A Congressional investigation into Biogen's controversial Alzheimer's drug Aduhlem was just released.
Aduhelm was developed by Cambridge, Massachusetts-based biotech company Biogen and Japanese pharmaceutical company Eisai.
The duo is currently developing another Alzheimer's drug, called lecanemab, which is expected to receive approval from the FDA in January and has shown more promising data in clinical trials.
Insider reviewed the 45-page investigation into Biogen's Alzheimer's drug.
Here are three of the most shocking takeaways:Biogen gave Aduhelm a crazy price tag despite knowing it would become inaccessible to many patientsFrom the moment Biogen announced Aduhelm's $56,000 price tag, the company faced backlash.
Organizations:
& $